Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

U.S. stock futures were little changed on Thursday night after the major averages slid following a lackluster earnings ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

The ad promotes, without identifying, semaglutide, the compounded versions of the weight-loss drugs Ozempic and Wegovy, and tirzepatide, the compounded version of Zepbound ... critical safety ...

As noted across the telehealth provider’s website and in the commercial’s fine print, compounded versions of drugs are not subject to FDA approval or evaluations of safety and quality.

Eli Lilly, the maker of Zepbound, offers a commercial savings ... broken or damaged wrapping or poor print quality — all indicators of an untrustworthy product. You should also avoid ordering ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

Ireland's pharmaceutical industry shipped billions' worth of goods to the U.S., but face threats from Trump 2.0.

A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company has taken the GLP-1 supply chain too far.